New horizons for targeted treatment of neuroendocrine tumors

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Neuroendocrine tumors (NETs) are rare and diverse, with limited randomized clinical trials.
• Understanding molecular targets is crucial for advancing NET treatment strategies.

Purpose of the Study:

• To summarize current standard therapies for NETs.
• To explore emerging therapeutic perspectives and molecular targets in NET treatment.

Main Methods:

• Review of existing literature on NET therapies.
• Analysis of randomized clinical trials and molecular pathway investigations.

Main Results:

• mTOR pathway inhibitors and tyrosine kinase inhibitors show efficacy.
• Somatostatin analogs improve progression-free survival and manage hormone-induced syndromes.

Conclusions:

• Targeted therapies, including mTOR inhibitors and somatostatin analogs, offer significant benefits for advanced NETs.
• NET treatment remains heterogeneous, necessitating further research and personalized approaches.